PAK5 and renal cell carcinoma: Our results both in vivo and in vitro demonstrated that miR-106a-5p could be a novel therapeutic target in the suppression of RCC metastasis, at least partially via the mediation of PAK5, with more profound mechanism awaiting further investigation.